Ignite Creation Date:
2025-12-25 @ 3:26 AM
Ignite Modification Date:
2025-12-26 @ 2:06 AM
Study NCT ID:
NCT01247805
Status:
COMPLETED
Last Update Posted:
2021-02-02
First Post:
2010-11-23
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Pivotal Bioequivalence Study Between The Sildenafil Powder For Oral Suspension (10 Mg/Ml) And The Sildenafil 10 Mg Immediate Release (IR) Tablet Relative To The Revatio 20 Mg IR Tablet In Healthy Volunteers Under Fasting Conditions
Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2011-01
Start Date Type:
None
Primary Completion Date:
2011-02
Primary Completion Date Type:
ACTUAL
Completion Date:
2011-02
Completion Date Type:
ACTUAL
First Submit Date:
2010-11-23
First Submit QC Date:
None
Study First Post Date:
2010-11-24
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-01-28
Last Update Post Date:
2021-02-02
Last Update Post Date Type:
ACTUAL